I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development

I-Corps：一种有效方法的转化潜力，可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒

• 批准号: 2420924
• 负责人: Dunbar Birnie
• 金额: $ 5万
• 依托单位: Rutgers University New Brunswick
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2024
• 资助国家: 美国
• 起止时间: 2024-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2420924&HistoricalAwards=false
• 关键词: Corps; Translation; potential; efficient; method

The broader impact of this I-Corps project is the development of a technology that prepares pathogens (viruses, bacteria, etc.) for use in vaccines through a rapid, simplified, low-cost manufacturing process. The technology works on pathogens that contain DNA (“DNA pathogens”). This solution holds promise because the method can be used to generate vaccines against any DNA pathogen, making the technology a platform relevant in both human and animal health markets (e.g., companion animals and livestock). The resulting vaccines will not need to be kept cold during shipping and storage, so it will be easier to get vaccines to places around the world. This attribute, in addition to the rapidity with which pathogens can be readied for vaccine production, means that the technology has the potential to quickly address epidemics and combat vaccine-preventable diseases worldwide. Long term, the technology will be validated to generate bacterial vaccines, important for antibacterial resistance. This technology should be attractive to researchers and vaccine manufacturers.This I-Corps project utilizes experiential learning coupled with a first-hand investigation of the industry ecosystem to assess the translation potential of the technology. This solution is based on the development of a technology that uses the chemical centanamycin to damage the DNA of pathogens and thereby produce live-attenuated, replication-defective pathogens that can be used to make vaccines. Previous studies have incorporated data using human cytomegalovirus and other pathogens and have demonstrated that a treated pathogen can infect cells but not replicate due to damaged DNA. The platform promises two key technical innovations for the vaccine industry: 1) since the solution is DNA pathogen-agnostic, the technique shows promise across all DNA-containing pathogens and 2) vaccines made with centanamycin-treated pathogens may not need cold storage and shipping. This innovation alone would be significant for addressing vaccine-preventable diseases worldwide.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响是开发一种技术，该技术通过快速，简化，低成本的制造过程来准备病原体（病毒，细菌等）以在疫苗中使用。该技术适用于含有DNA的病原体（“ DNA病原体”）。该解决方案具有希望，因为该方法可用于针对任何DNA病原体生成疫苗，使该技术成为人类和动物健康市场（例如，伴侣动物和牲畜）的平台。最终的疫苗在运输和存储期间不需要保持冷，因此将疫苗接种到世界各地会更容易。除了可以对疫苗生产进行病原体的速度，该属性还意味着该技术有可能快速解决全球范围内的发作并打击可预防疫苗的疾病。长期，该技术将得到验证以生成细菌疫苗，这对于抗菌耐药性很重要。该技术应该对研究人员和疫苗制造商有吸引力。这个I-Corps项目利用专家学习以及行业生态系统的第一手投资来评估技术的翻译潜力。该解决方案是基于一种使用化学六霉素损害病原体DNA的技术的开发，从而损害了可用于生产疫苗的实时衰减，复制缺陷的病原体。先前的研究已使用人类巨细胞病毒和其他病原体纳入了数据，并证明已治疗的病原体可以感染细胞，但由于DNA损伤而不能复制。该平台承诺为疫苗行业提供两项关键的技术创新：1）由于解决方案是DNA病原体 - 敏捷剂，因此该技术在所有含DNA的病原体和2）用Centanamycin治疗的病原体制成的疫苗可能不需要冷藏和运输。仅这项创新对于解决全球疫苗的可预防疾病就将是重要的。该奖项反映了NSF的法定任务，并且使用基金会的知识分子优点和更广泛的影响评估标准，认为通过评估被认为是宝贵的支持。